PAPILLON Final Survival Analysis Requires Crossover Context

Company Johnson & Johnson Innovative Medicine Event Type Clinical Trial Results (Phase III, Final Overall Survival Analysis) Modality Bispecific Antibody (EGFR x MET) Asset Amivantamab (Rybrevant) Target EGFR and MET Disease Area EGFR Exon 20 Insertion-Positive Advanced Non-Small Cell Lung Cancer Summary The final overall-survival…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Tags
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *

Saturday Rounds

MeiraGTx – $400M Oberland Strategic Financing for Late-Stage Gene Therapy Programs
Aureka Raises $100 Million for AI-Native Drug Discovery
Solstice Oncology Launches with $225 Million Series A
Beeline Therapeutics – $300M Launch